Humacyte Income Statement (2020-2026) | HUMA

Income Statement Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.24M0.52M0.30M0.75M0.47M0.49M
Cost of Revenue (Quarter)
0.15M0.21M0.26M9.08M2.04M
Gross Profit (Quarter)
0.37M0.09M0.49M-8.62M-1.54M
Operating items
Research & Development (Quarter)
14.57M15.39M16.25M16.31M14.65M17.34M14.96M17.28M20.54M18.55M20.18M21.26M23.75M22.93M20.66M15.42M22.01M17.27M14.61M19.46M
Selling, General & Administrative (Quarter)
5.39M5.40M5.55M5.68M5.18M6.19M5.83M5.23M6.19M6.07M6.00M5.31M5.75M7.31M7.43M8.14M7.81M7.61M7.62M7.93M
Other Operating Expenses (Quarter)
0.15M0.21M0.26M9.08M2.04M
Operating Expenses (Quarter)
19.96M20.78M21.80M22.00M19.83M23.52M20.79M22.51M26.73M24.62M26.18M26.58M29.50M30.23M28.09M23.70M30.03M25.14M31.30M29.43M
Operating Income (Quarter)
-19.27M-20.54M-21.63M-21.76M-18.53M-23.49M-20.81M-22.51M-26.73M-24.62M-26.18M-26.58M-29.50M-30.23M-28.10M-23.20M-29.73M-24.39M-30.84M-28.93M
EBIT (Quarter)
-19.27M-20.54M-21.63M-21.76M-18.53M-23.49M-20.81M-22.51M-26.73M-24.62M-26.18M-26.58M-29.50M-30.23M-28.10M-23.20M-29.73M-24.39M-30.84M-28.93M
Non-operating items
Non Operating Investment Income (Quarter)
12.00
Interest & Investment Income (Quarter)
0.00M0.00M0.01M0.03M0.30M0.88M1.41M1.48M1.48M1.37M1.14M1.03M1.31M0.91M0.85M0.66M0.83M0.59M0.50M0.33M
Other Non Operating Income (Quarter)
3.30M0.42M-0.04M-2.40M-0.14M0.02M0.06M-0.39M1.05M-0.72M14.93M-0.75M4.01M20.57M8.53M
Non Operating Income (Quarter)
2.07M-11.02M64.21M1.93M55.40M-1.79M17.07M-14.46M4.03M-1.37M1.08M-5.32M-27.16M-8.97M7.15M62.32M-7.93M6.88M6.03M11.32M
Net income details
EBT (Quarter)
-20.48M-21.74M-23.01M-23.16M-19.72M-24.25M-21.04M-22.74M-26.96M-24.72M-26.77M-27.36M-30.70M-31.76M-29.76M-25.54M-31.44M-26.41M-33.43M-30.88M
Profit After Tax (Quarter)
-17.20M-31.56M42.59M-19.83M36.87M-25.28M-3.72M-36.97M-22.71M-26.00M-25.11M-31.90M-56.66M-39.20M-20.94M39.14M-37.66M-17.51M-24.80M-17.62M
Income from Continuing Operations (Quarter)
-20.48M-21.74M-23.01M-23.16M-19.72M-24.25M-21.04M-22.74M-26.96M-24.72M-26.77M-27.36M-30.70M-31.76M-29.76M-25.54M-31.44M-26.41M-33.43M-30.88M
Consolidated Net Income (Quarter)
-20.48M-21.74M-23.01M-23.16M-19.72M-24.25M-21.04M-22.74M-26.96M-24.72M-26.77M-27.36M-30.70M-31.76M-29.76M-25.54M-31.44M-26.41M-33.43M-30.88M
Income towards Parent Company (Quarter)
-20.48M-21.74M-23.01M-23.16M-19.72M-24.25M-21.04M-22.74M-26.96M-24.72M-26.77M-27.36M-30.70M-31.76M-29.76M-25.54M-31.44M-26.41M-33.43M-30.88M
Net Income towards Common Stockholders (Quarter)
-20.48M-21.74M-23.01M-23.16M-19.72M-24.25M-21.04M-22.74M-26.96M-24.72M-26.77M-27.36M-30.70M-31.76M-29.76M-25.54M-31.44M-26.41M-33.43M-30.88M
Additional items
EPS (Basic) (Quarter)
-2.89-0.723.03-0.190.36-0.25-0.04-0.36-0.22-0.25-0.24-0.29-0.48-0.33-0.160.28-0.24-0.11-0.15-0.09
EPS (Weighted Average and Diluted) (Quarter)
-2.89-0.723.03-0.190.35-0.25-0.04-0.36-0.22-0.25-0.24-0.29-0.48-0.33-0.160.28-0.24-0.11-0.15-0.09
Shares Outstanding (Weighted Average) (Quarter)
5.94M43.95M0.41M103.00M103.01M103.01M103.05M5.59M103.36M103.44M103.42M108.25M119.17M5.59M14.08M131.50M143.53M158.31M40.94M197.85M
Shares Outstanding (Diluted Average) (Quarter)
5.91M43.95M39.97M103.00M103.92M103.03M103.05M103.26M103.36M103.44M103.42M108.25M119.17M119.41M118.48M131.76M155.44M148.51M158.16M
EBITDA (Quarter)
-17.20M-31.56M42.59M-19.83M36.87M-25.28M-3.72M-36.97M-22.71M-26.00M-25.11M-31.90M-56.66M-39.20M-20.94M39.14M-37.66M-17.51M-30.84M-28.93M
Interest Expenses (Quarter)
1.22M1.20M1.40M1.43M1.49M1.64M1.64M1.70M1.71M1.46M1.73M1.82M2.52M2.44M2.51M3.00M2.54M2.61M3.09M2.27M